



APPLICATIONS OF PRODRUG FOR TARGETED CANCER THERAPY

¹Mr. Shailesh Farkade, ²Ms. Priyanka Shelke, ³Dr. Gajanan Sanap, ⁴Mr. Aniket Bankar

¹Student, ²Assistant Professor, ³Principal, ⁴Student

¹Department of Pharmacy,

¹Late Bhagirathi Yashwantrao Pathrikar College of Pharmacy, Pathri, Aurangabad, 431001. Maharashtra, India.

Abstract: Prodrugs are extensively used within the focused transport of cytotoxic compounds to most cancer cells. To date, focused prodrugs for most cancers remedy have executed an amazing range in phrases of goal selection, activation chemistry, in addition to length and physicochemical nature of the prodrug. In this review, we discover a unified view of most cancer-focused prodrugs and spotlight numerous examples from recombinant generation that exemplify the prodrug idea however aren't recognized as such. Recombinant "prodrugs" which includes engineered anthrax toxin display promise in organic specificity via the conditionally focused on of a couple of cell markers. Conditional focused on is executed via way of means of structural complementation, the spontaneous meeting of engineered inactive subunits or fragments to reconstitute functional activity.

Keywords - Cancer, Complementation, Conditional Biospecificity, Prodrugs, Targeted Therapy.

I. INTRODUCTION

"A prodrug is a medicine or drug or compound that, after administration, is metabolized (i.e., transformed in the body) into a pharmacologically active drug. Instead of administering a drug directly, a corresponding prodrug may be used to enhance how the drug is absorbed, distributed, metabolized, and excreted (ADME)."

Targeted remedy is the corner stone of current most cancer treatment. For cancers which can be absolutely characterized with the aid of using uniquely aberrant markers, reagents that inhibit or target those markers are super therapeutics with minimum negative results on regular tissues. The medical achievement of imatinib (Gleevec®), for example, which targets the Bcr-Abl tyrosine kinase, is at once because of the particular and informal function of the Bcr-Abl oncoprotein in continual myeloid leukemia and related "Philadelphia chromosome" leukemias [1]. During the beyond decades, the improvement of novel strategies to focus on the transport and activation of prodrugs has been rapid, varied, and impressive. The information of those advances were documented in numerous latest reviews [2-6]. Here, our intention is to offer a unified view of the prodrug idea in focused most cancer remedy. Specifically, we are able to spotlight the useful equivalence of reputedly disparate cell-focused on schemes, and the way such schemes can also additionally supplement every different in focused on complicated most cancer phenotypes primarily based totally on or extra molecular markers.

II. PASSIVELY ACTIVATED CANCER-TARGETED PRODRUGS

A various variety of chemistry has been evolved to cause the activation of cancer-centered prodrugs to their cytotoxic opposite numbers in situ (Fig. 1a). Broadly, those techniques may be defined as passive or active. Passive techniques employ aberrant nearby physicochemical (e.g., decreased pH, hypoxia) or physiologic changes (e.g., overexpression of floor receptors) in tumor tissue to supply or bioactivate prodrugs thru a single step. Active techniques use prodrugs with specialized activation chemistry that need to be proffered with the aid of using a separate, target-directed exogenous enzyme (directed enzyme/prodrug therapy).




Fig1– A) Passive and B) Active Conversion of Prodrug

• Passive and active conversion of prodrugs: -

Shown are illustrative examples of prodrugs which can be activated via way of means of endogenous (passively) or exogenous (actively) enzymes, proteins, or conditions. In the case of conjugates, the energetic drug moiety is coloured in red.

Examples of prodrugs which can be substrates for endogenous proteases

- ① prostate-unique antigen, PSA^[8], membrane transporters
- ② PEPT1 oligopeptide transporter in pancreatic carcinomas^[14], or intracellular reductases
- ③ DT-diaphorase and
- ④ NADPH:cytochrome P450 reductase. b Prodrugs requiring exogenously administered enzymes or strength for activation. Activation of 5-fluorocytosine
- ⑤ 5-FC and gemcitabine
- ⑥ dFdC via way of means of engineered chimeric enzymes to their first cytotoxic antimetabolites. “Designer” conjugates of cytotoxic compounds as substrates for unique exogenous enzymes:
- ⑦ a recombinant carboxylesterase for dipiperinyl-VP-16^[40] and
- ⑧ β -lactamase for cephalosporinyl-5-FU.^[41]
- ⑨ A conjugate of the photosensitizer chlorin e6 with a single-stranded DNA aptamer that objectives epithelial cancers providing hypo-glycosylated MUC1 antigens^[20], irradiation at 664 nm generates cytotoxic singlet oxygen.

Studies in most cancers' biology have discovered an extensive variety of enzymes which might be aberrantly upregulated in most cancers' cells. Many proteases are actually acknowledged to be over expressed in tumors and make contributions to a competitive or metastatic phenotype. These enzymes may be focused via way of means of incorporating suitable substrates into the prodrug structure. The maximum not commonly consist of lysosomal proteases along with the cathepsins and legumain (enzymes), in addition to proteases located withinside the extracellular matrix (ECM) along with the matrix metalloproteases (MMPs) and urokinase-kind plasminogen activator (uPA). Targeting is done via way of means of incorporating a sequence-particular peptide linker as a “trigger” moiety that save you unfastened diffusion of the prodrug into cells but, upon cleavage, releases the cytotoxic agent^[7]. In the case of ECM proteases, tropism for tumors is conferred via way of means of proximity of the enzymes close to the focused cell's surface. For example, a tissue-particular protease withinside the ECM is prostate-particular antigen (PSA), which has been focused in prostate most cancers via way of means of conjugating doxorubicin^[8] or with L12ADT^[9], a thapsigargin analog (a disruptor of intracellular Ca²⁺ homeostasis), to the PSA-particular peptide substrate HSSKLQ. Similarly, doxorubicin has been focused at MMP-expressing fibrosarcoma cells via way of means of conjugation with a artificial MMP-selective peptide substrate^[10]. Non-proteolytic targets, inclusive of cell-surface receptors which can be

aberrantly overexpressed on most cancers cells, also can be centered with the aid of using prodrug conjugates harboring ligands for those receptors. Many of those receptors go through endocytosis or delivery substrates and consequently act as precise portals into cells. Targeting ligands varies broadly in chemistry. Due to their availability or ease of synthesis, folic acid and short peptides are of the maximum common ligands in centered prodrug conjugates. Folic acid conjugates target the folate receptor (FR) that is differentially overexpressed on many most cancers cells and reachable from systemic circulation^[11]. Among peptides, the tripeptide RGD (Arginylglycylaspartic acid) and their cyclic derivatives are broadly used to goal integrins and floor protein aminopeptidase N (APN, additionally called CD13), each of which might be particularly expressed in tumor-brought about angiogenesis^[12,13].

Mono- and di-amino acid prodrugs of floxuridine have additionally been mentioned to goal the PEPT1 transporter that is particularly expressed in a few pancreatic adenocarcinomas^[14]. Bulkier ligands consist of peptide hormones inclusive of somatostatin and vasoactive intestinal peptide; increase factors/cytokines inclusive of epidermal increase factor (EGF) and numerous interleukins; in addition to antibodies (antibody-drug conjugate, or ADC)^[15]. The anti-microtubule agent mertansine (DM1) has been utilized in numerous clinically a success ADCs, along with a conjugate with trastuzumab (T-DM1) to target the HER2 receptor^[16], a cell-floor target in metastatic breast most cancers. Saccharides constitute some other elegance of focused on ligands, starting from galactose to goal the asial-glycoprotein receptor expressed selectively in hepatomas^[17], to the polysaccharide hyaluronic acid that binds CD44 on many epithelial cancers^[18]. A class of ligands utilized in centered prodrug conjugates includes sellers derived absolutely from in vitro selection, inclusive of affibodies (compact folded proteins) and nucleic acid aptamers (folded single-stranded DNA or RNA). These “artificial” ligands are mainly treasured for focused on disease-associated targets for which no endogenous ligand exists. Examples consist of affibodies for the HER2 receptor^[19], and DNA aptamers for the hypo-glycosylated MUC1 antigen^[20]. Finally, intracellular targets may be applied as well. DT-diaphorase (DTD) is a cytosolic enzyme that mediates the two-electron reductase of quinone substrates. DTD stages are extended in some of tumor types, which include non-small cellular lung carcinoma, colorectal carcinoma, liver most cancers, and breast carcinoma^[21]. DTD can bioreductively set off an extensive variety of quinones, appreciably the conventional DNA cross-linker mitomycin C. Designer alkylating dealers along with RH1 (presently in scientific trials in breast most cancers) employ the bioreduction of a connected quinone to selectively set off aziridine-primarily based totally mustards in most cancers’ cells^[22]. Another intracellular most cancer’s goal is telomerase, a typically repressed enzyme this is energetic in pancreatic and different cancers^[23]. Telomerase hydrolyzes acycloguanosyl 5'-thymidyltriphosphate, a thymidine analog prodrug, to acyclovir diphosphate (the energetic shape of acyclovir)^[24]. An alternative technique to concentrated on precise cellular targets is to target aberrant physicochemical functions of the tumor microenvironment.

Hypoxia may be passively centered with prodrugs which might be activated through metabolic reduction^[25]. A foremost group of hypoxia-activated prodrugs is represented through nitroheterocycles, which showcase a number bioreductive chemistry, which include activation of nitro substituents to numerous labile species or fragmentation to release energetic moieties^[26]. For instance, 2-methylimidazole has been integrated as a cause moiety in numerous prodrugs concentrated on hypoxic most cancers cells. BCCA621C is one such instance that goals chronically hypoxic most cancers cells wherein DNA-established protein kinase (DNA-PK), a prime thing of the restore pathway for double-strand breaks, is induced^[27]. One-electron reduction (for instance, through NADPH-established P450 reductase) ends in a volatile radical anion that releases the DNA-PK inhibitor IC86621 and complements the radiosensitivity of hypoxic lung most cancers cells.^[28] Similarly, leukemic cells in hypoxic bone marrow may be centered with a 2-methylimidazole conjugate of bromo-isophosphoramidate mustard termed TH-302^[29]. Coordination complexes containing metallic facilities which might be able to redox chemistry additionally constitute bioreductively activated prodrugs. Oxidized analogs of cisplatin and different platinating agents, wherein the platinum middle exists as Pt(IV), are kinetically much less reactive cross-linkers relative to Pt(II) and are used in lots of prodrug designs. Satraplatin, a Pt(IV) analog of cisplatin, is presently below research as an orally bioavailable platinating agent.^[30] Importantly, the oxidized Pt(IV) state stably coordinates axial ligands which might be absent withinside the extra biologically lively Pt(II) state. Short peptides containing RGD and NGR motifs had been conjugated to Pt(IV)(NH₃)₂Cl₂ to goal integrins and APN.^[31] Reduction through intracellular thiols hastily generates cisplatin. A reversed position for the metallic middle is observed in cobalt(III) coordination complexes which act as prodrug “chaperones” through freeing their healing ligands upon discount to cobalt(II).^[32] Targeting may be moreover subtle through manipulating the internet charge on a prodrug, to take benefit of the distinctly acidic (0.5 to at least 1 pH unit decrease than physiologic) of the tumor microenvironment.

III. ACTIVE CONVERSION OF CANCER-TARGETED PRODRUGS

To amplify the target repertoire past endogenous activators or conditions, exogenous enzymes may be focused at most cancers cells to prompt a selected inactive substrate (prodrug), that's administered separately, to a cytotoxic product (Fig. 1b). In those applications, cytosine deaminase (CD) is traditionally the maximum generally used enzyme. Recombinant CD, cloned from a bacterial, yeast, or fungal source, converts the prodrug 5-fluorocytosine (5-FC) to 5-fluorouracil (5-FU), whose downstream antimetabolites result in a so-called “thymineless death.” More recently, a yeast cytosine deaminase/uracil phosphoribosyltransferase fusion (CD/UPRT; encoded via way of means of the Fcy::Fur gene) has been brought as an extra green opportunity to generate the 5-FU-primarily based totally antimetabolites.^[33] Other antimetabolite prodrugs encompass the nucleoside analogs consisting of acyclovir and ganciclovir, which can be activated to their lively triphosphate the usage of recombinant thymidylate kinase from herpes simplex virus,^[34] in addition to 6-methyl-2'-deoxyribose and 2-fluoro-2'-deoxyadenosine, which can be transformed via way of means of Escherichia coli purine nucleoside phosphorylase to 6'-methylpurine and 2-fluoroadenine, respectively.^[35] Concerns with immunogenicity because of the non-human beginning of the activating enzymes may be addressed via way of means of using engineered human deoxycytidine kinase (DCK) and thymidylate kinase (tmpk) able to mono-phosphorylating a selection of (non-physiologic) prodrugs consisting of gemcitabine (dFdC), bromovinyl-deoxyuridine (BVdU), cytarabine (AraC), and 3'-azido-3'-deoxythymidine (AZT) monophosphate.^[36,37] A chimeric fusion of DCK with uridine monophosphate kinase (DCK::UMK) has additionally been advanced to immediately prompt gemcitabine to its cytotoxic diphosphate metabolite (dFdCDP) in pancreatic carcinoma.^[38] There are additionally “designer” prodrugs wherein a chemotherapeutic agent is derivatized to a substrate for a selected activating enzyme. Examples encompass phenoxyacetamide conjugates of doxorubicin and melphalan which can be hydrolyzed via way of means of penicillin-V

amidase,^[39] a dipiperidinyl conjugate of etoposide (VP-16) this is hydrolyzed via way of means of a recombinant carboxylesterase,^[40] and a cephalosporin conjugate of 5-FU designed for hydrolysis via way of means of β -lactamase.^[41]

In enzyme-activated prodrug therapy, many focused procedures for transport of the activating enzymes now exist. The enzyme can be directed to most cancers cells as a conjugate with an antibody (antibody-directed enzyme/prodrug therapy, ADEPT), as polymer-primarily based totally nanoparticles (PDEPT), genetically the usage of engineered non-replicative viruses (GDEPT) or maybe complete cells.^[42,43] In particular, the hypoxic tumor microenvironment, which hinders passive drug distribution, may be focused the usage of engineered bacterial spores of the anaerobic *Clostridium* sp. harboring genes that encode prodrug-activating enzymes (CDEPT).^[44] This technique combines the concentrated on and transducing functionality of *Clostridia* with their intrinsic bacteriolytic properties. Recently, engineered tumor-tropic *Salmonella typhimurium* has additionally been reported.^[45] In addition to chemical triggers, bodily triggers may be hired to prompt cytotoxic prodrugs externally. Photodynamic therapy (PDT) has hooked up itself as a beneficial remedy for lots strong tumors. In PDT, seen or near-infrared mild is used to photo-prompt inert prodrugs to cytotoxic agents. Examples encompass the photo-activation of chlorin e6^[46] to generate tremendously reactive singlet oxygen species, and platinum(IV)-primarily based totally prodrugs to lively platinum(II) species.^[47] PDT stocks a few similarities with radiosensitizing prodrugs, and the loco-nearby irradiation in keeping with se can be taken into consideration as focused therapy. However, PDT has the gain of the usage of a ways much less unfavorable radiation and missing the immunosuppressive toxicity of radiotherapy.

IV. TARGETED MACROMOLECULAR PRODRUGS

Historically, prodrug approaches in centered cures had been related to chemical or enzymatic activation of low-molecular-weight compounds. More recently, the scientific achievement of the liposomal doxorubicin (DOX) product Doxil® in reaching equal anticancer efficacy as loose DOX, even as drastically decreasing off-target toxicity,^[48] has inspired the system of many nonspecific chemotherapeutics as nanoparticles. Nanoparticles up to ~a hundred nm in length can extravasate efficaciously via endothelial gaps in tumorvasculature and preferentially acquire in strong tumors, a phenomenon termed the improved permeability and retention (EPR) impact.^[49] Small molecules inside a huge variety of physicochemical parameters enjoy quite few impediments in distribution into cells and subcellular compartments. Compared to low-MW counterparts, macromolecules have to triumph over precise obstacles to attain theiraction (e.g., nucleus for platinating marketers). Unlike small molecules which can freely diffuse throughout organic membranes, macromolecular marketers can most effectively input stay cells through endocytic pathways. Many mobileular-floor receptors and antigens function regulated portals for mobileular access if centered with ligands.^[50]

In reaction to those opportunities, a huge variety of conjugate techniques has been developed. Many of those tactics make bigger without delay from low-molecular weight conjugates. Antibody-drug conjugates (ADC), for example, are macromolecular analogs of low-MW prodrug conjugates wherein a chemotherapeutic is related to an antibody through engineered linkers. These linkers are cleavable below precise physicochemical conditions (low pH, decreasing environment) or with the aid of using precise enzymes (including esterases or precise ECM or lysosomal proteases), liberating the lively drug whilst the conjugate encounters the centered endogenous enzyme or condition. Another essential elegance of macromolecular prodrugs is represented with the aid of using polymer-drug conjugates (Fig. 2b), wherein low-molecular weight cytotoxins are conjugated through labile linkers to hydrophilic, biocompatible polymers including N-(2-hydroxypropyl)methacrylamide copolymers (HPMA).^[51] In addition to the cytotoxic agent, mobileular-focused on moieties (including receptor ligands, antibodies, or aptamers) also can be anchored to the polymeric backbone, retaining a unitary centered polymer-drug conjugate. In addition, many such structures contain self-immolative linkers (or spacers) that spontaneously fragment whilst caused with the aid of using a number one centered occasion.^[52] This generation permits the simultaneous launch of a couple of equivalents of drug from a unmarried triggering occasion to make bigger the cytotoxic impact upon bioactivation.




Fig 2 – Diversity of Targeted Macromolecule Prodrug Conjugate

Diversity of centered macromolecular prodrug conjugates. Shown are illustrative examples of cytotoxic agents (drawn in red) which can be covalently connected to focused on moieties (blue) to shape macromolecular prodrug conjugates. In a few cases, a mainly cleavable linker (or spacer; green) connects the drug and focused on moiety. Cleavage sites are marked with a dashed line; enzyme-mediated cleavage is denoted with a scissors symbol.

a. Antibody-drug conjugates (ADCs), together with trastuzumab emtansine (T-DM1), wherein the anti-tubular agent DM1 is conjugated to trastuzumab that goals HER2-high-quality metastatic breast most cancers.^[16] In T-DM1, there are on common $n = 3.5$ equivalents of DM1 in step with antibody.

b. Targeted polymer-drug conjugates. HPMA-primarily based totally copolymers are regularly used as a biocompatible polymeric scaffold to shape polymeric nanoparticles.

① A pH-touchy HPMA-doxorubicin conjugate wherein the drug and anti-thymocyte globulin are related at unique HPMA units. Release of doxorubicin is prompted via way of means of hydrolysis of a hydrazone linker at endosomal pH (5 to 6).

② In HPMA-JHPD, L12ADT (an alkylated thapsigargin analog) targets prostate most cancers cells through a sequence-particular peptide linker this is cleaved via way of means of prostate-particular antigen.

③ Carbon nanotube as a singular macromolecular provider for Pt(IV)-primarily based totally prodrugs. The focused on moiety (folic acid) and “longboat” provider are anchored to the 2 axial positions found in Pt(IV), which might be removed whilst the metallic middle is decreased to Pt(II), producing cisplatin, beneathneath intracellular conditions.^[53]

c. Redirected toxins, exemplified via way of means of the immunotoxin moxetumomab pasudotox, that is a recombinant conjugate of an anti-CD22 single-chain variable fragment (scFv) to residues 251 to 613 of Pseudomonas exotoxin A.

Cytotoxicity encoded in area III (PE3) is conditionally activated via way of means of furin-mediated cleavage among residues 279 and 280 in area II. In addition to traditional biocompatible polymers, novel substances together with carbon nanotubes are moreand more more used to assemble macromolecular prodrugs. In the case of platinating agents, the axial positions of Pt(IV) prodrugs had been used to connect them to nanotubes in addition to cell-focused on ligands.^[53,54] As with their low-molecular weight Pt(IV) counterparts, intracellular bioreduction releases the reactive Pt(II) species. Carbon nanotubes showcase photo-excitation residences and also can act as substrate for PDT to provide reactive singlet oxygen.^[46] In this way, the nano-provider can itself exert a healing impact via way of means of serving a 2nd, light-activating prodrug. Besides direct conjugation to a polymeric scaffold, prodrug nanoparticles also can be attained thru noncovalent assembly. Pt(IV)(NH₃)Cl₂ has been derivatized on the axial positions with hexyl chains to impart solubility withinside the indoors of a PLGA-PEG copolymer, to which an aptamer focused on prostate-particular membrane antigen (PSMA) is conjugated ^[55]. Since the indoors of nanoparticles is greater hydrophobic than bulk solution, the layout objective of one of these prodrugs is to maximise its solubility for encapsulation,

instead of to connect the moiety at once. In the case of exceptionally hydrophobic drugs, they had been integrated at once as an issue of amphiphilic polymers to shape micelles or liposomes. For example, paclitaxel has been conjugated with poly(ethyl ethylene phosphate) and folic acid.^[56] Similarly, phytosphingosine (an anticancer sphingolipid metabolite) has been conjugated with poly(2-hydroxyethyl L-aspartamide) and folic acid.^[57] In each case, the consequent amphiphilic conjugates self-gather to shape FR-focused on polymeric micelles able to loading a 2nd drug (together with doxorubicin), forming two-drug nanoparticles. Hydrolytic cleavage of the polymer at endosomal pH releases each the conjugated drug withinside the polymer provider in addition to the shipment drug. Finally, hydrophobic anticancer ether lipids had been conjugated as phosphoglycerol and phosphocholine analogs that self-gather into strong liposomes.^[58] Cleavage of the phospholipids via way of means of secretory phospholipase PLA2 (sPLA2), that is extended in numerous epithelial cancers, releases the poisonous ether lipids. In summary, those examples spotlight the trend in centered most cancers prodrugs toward macromolecular platforms, which encompass the prodrug idea thru a broader variety of procedures relative to their low-molecular weight counterparts.

V. PROTEIN THERAPEUTICS AS A TARGETED CANCER PRODRUGS

At its core, focused most cancers remedy is worried with the selective transport of biologically lively payloads to the tumor cells *in vivo*. It is obvious from the foregoing and different reviews^[2-6] that conjugates of cytotoxic agents to the total gamut of focused on carriers (ligand-, antibody-, polymer-drug conjugates) represent a main swath of focused most cancers prodrugs, which launch the cytotoxic moiety upon attaining their meant web website online of action. The variety of focused prodrug conjugates in step with se underscores the overall applicability of this approach. In this light, it's miles beneficial to consist of sure protein therapeutics on this discussion. Protein pollutants from a lot of bacterial, fungal, and plant reassets are distinctly effective cytotoxins whose ability as ablative healing sellers has been investigated for lots decades. In our view, there's little cause in opposition to a greater unified view of focused prodrug conjugates. Like prodrug conjugates, many focused pollutants encompass a focused-on moiety (e.g., an antibody, withinside the case of immunotoxins), a cleavable linker, and a drug (cytotoxic enzyme). Moxetumomab pasudotox, the maximum clinically superior immunotoxin presently in medical trials for numerous leukemias and lymphomas, is a bonafide instance of this concept. It includes a truncated exotoxin A from *Pseudomonas aeruginosa* wherein the local receptor-binding domain (placed withinside the N-terminal 250 residues) has been changed with a single-chain variable fragment focused on the cell-floor CD22 antigen.^[59] Cytotoxic interest is conferred completely via way of means of the C-terminal segment (residues 405 to 613, termed PE3). As is, this conjugate is an inactive toxin: cytotoxic activation calls for cleavage via way of means of the protease furin in the course of endocytosis among residues 279 and 280.^[60]

Beyond Targeting Single Phenotypes: Conditional Multi-precise Targeting Currently, the bulk of focused healing approaches, consisting of prodrugs, target a single molecular goal or condition. These prodrugs are consequently monospecific with appreciate to their mode of activation, and are commonly distinctly pharmacologically precise. While a few cancers may be uniquely differentiated via way of means of a single target, maximum illnesses present greater complicated cellular phenotypes which includes a couple of molecular objectives which might be mutated or overexpressed. As a result, monospecific sellers can be distinctly selective pharmacologically (for the marker) however be inadequately selective biologically. For instance, due to the fact the HER2 receptor, a main marker in metastatic breast most cancers, is likewise determined on myocardial tissues, trastuzumab and its conjugates that focus on HER2 by myself cause cardiotoxicity *in vivo*.^[61]




Fig 3 – Off-targeted Toxicity in cells expressing one of the Targeted Receptor and Target Cell

Off-target effects of transductionally bispecific toxin conjugates. A cool animated film displaying the diverse mobile interactions of bispecific toxin conjugates harboring receptor-focused on ligands (blue and red). Since binding via way of means of every ligand to its focused receptor is independent, and every receptor is successful is endocytosis, intoxication ensues in all cells harboring one or each of the focused cell-surface receptors. Activity in ordinary cells harboring most effective one of the focused receptor results in off-goal, dose-restricting toxicity.

VI. CONCLUSION

The prodrug idea is applied in focused most cancers remedy extra pervasively than the usage of the time period currently indicates. In addition to small-molecule and polymer-primarily based totally methods, recombinant methods are nicely included beneath the prodrug umbrella. In this review, we've got followed an inclusive view of the prodrug idea and highlighted examples of recombinant era that recommend a promising function for complementation as a method to noticeably enlarge the prodrug technique to goal complicated most cancers phenotypes. Certainly, those are forward-wondering ideas with a purpose to require sizeable extra characterization to set up their healing capability relative to cutting-edge agents. Recombinant methods leverage a enormous frame of pharmaceutical understanding from protein- and gene-primarily based totally bio-therapeutics and are already advancing GDEPT via the aggregate of prodrug activation and viral oncolysis. We expect that medicinal chemistry, polymer

science, and recombinant methods will preserve to reap new synergy in concentrated on specificity, discount of host toxicity, and pharmacokinetic optimization.

VII. REFERENCES

- [1] Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. *Annals of internal medicine*. 2003 May 20;138(10):819-30.
- [2] Singh A, Boldin-Adamsky S, Thimmulappa RK, Rath SK, Ashush H, Coulter J, Blackford A, Goodman SN, Bunz F, Watson WH, Gabrielson E. RNAi-mediated silencing of nuclear factor erythroid-2–related factor 2 gene expression in non–small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. *Cancer research*. 2008 Oct 1;68(19):7975-84.
- [3] Han HK, Amidon GL. Targeted prodrug design to optimize drug delivery. *Aaps Pharmsci*. 2000 Mar;2(1):48-58.
- [4] de Albuquerque Silva AT, Chung MC, Castro LF, Carvalho Guido RV, Ferreira EI. Advances in prodrug design. *Mini reviews in medicinal chemistry*. 2005 Oct 1;5(10):893-914.
- [5] Kratz F, Müller IA, Ryppa C, Warnecke A. Prodrug strategies in anticancer chemotherapy. *ChemMedChem: Chemistry Enabling Drug Discovery*. 2008 Jan 11;3(1):20-53.
- [6] Mahato R, Tai W, Cheng K. Prodrugs for improving tumor targetability and efficiency. *Advanced drug delivery reviews*. 2011 Jul 18;63(8):659-70.
- [7] Choi KY, Swierczewska M, Lee S, Chen X. Protease-activated drug development. *Theranostics*. 2012; 2 (2): 156–78. Epub 2012/03/09. doi: 10.7150/thno.4068 PMID: 22400063;.
- [8] Denmeade SR, Nagy A, Gao J, Lilja H, Schally AV, Isaacs JT. Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. *Cancer research*. 1998 Jun 15;58(12):2537-40.
- [9] Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garrett ES, Lilja H, Christensen SB, Isaacs JT. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. *Journal of the National Cancer Institute*. 2003 Jul 2;95(13):990-1000.
- [10] Albright CF, Graciani N, Han W, Yue E, Stein R, Lai Z, Diamond M, Dowling R, Grimminger L, Zhang SY, Behrens D. Matrix metalloproteinase–activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity. *Molecular cancer therapeutics*. 2005 May 1;4(5):751-60.
- [11] Low PS, Antony AC. Folate receptor-targeted drugs for cancer and inflammatory diseases. *Advanced drug delivery reviews*. 2004 Apr 1;56(8):1055-8.
- [12] Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, Ashmun RA, Shapiro LH, Arap W, Ruoslahti E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. *Cancer research*. 2000 Feb 1;60(3):722-7.
- [13] Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. *Nature Reviews Cancer*. 2002 Feb;2(2):91-100.
- [14] Dhanabal M, Wu F, Alvarez E, McQueeney KD, Jeffers M, MacDougall J, Boldog FL, Hackett C, Hackett C, Shenoy S, Khrantsov N. Recombinant semaphorin 6A-1 ectodomain inhibits in vivo growth factor and tumor cell line-induced angiogenesis. *Cancer biology & therapy*. 2005 Jun 1;4(6):659-68.
- [15] Ducry L, Stump B. Antibody– drug conjugates: linking cytotoxic payloads to monoclonal antibodies. *Bioconjugate chemistry*. 2010 Jan 20;21(1):5-13.
- [16] Phillips GL, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari R. V, RJ Lutz, WL Wong, FS Jacobson, H. Koeppen, RH Schwall, SR Kenkare-Mitra, SD Spencer and MX Sliwkowski, “Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate,”. *Cancer Research*. 2008;68(22):9280-90.
- [17] Seymour LW, Ulbrich K, Strohalm J, Duncan R. Pharmacokinetics of a polymeric drug carrier targeted to the hepatocyte galactose receptor. *Br. J. Cancer*. 1991;63:859-66.
- [18] Oh EJ, Park K, Kim KS, Kim J, Yang JA, Kong JH, Lee MY, Hoffman AS, Hahn SK. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. *Journal of Controlled Release*. 2010 Jan 4;141(1):2-12.
- [19] Orlova A, Magnusson M, Eriksson TL, Nilsson M, Larsson B, Höidé-Guthenberg I, Widström C, Carlsson J, Tolmachev V, Ståhl S, Nilsson FY. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. *Cancer research*. 2006 Apr 15;66(8):4339-48.
- [20] Ferreira CS, Cheung MC, Missailidis S, Bisland S, Gariépy J. Phototoxic aptamers selectively enter and kill epithelial cancer cells. *Nucleic acids research*. 2009 Feb 1;37(3):866-76.
- [21] Danson S, Ward TH, Butler J, Ranson M. DT-diaphorase: a target for new anticancer drugs. *Cancer treatment reviews*. 2004 Aug 1;30(5):437-49.
- [22] Hargreaves RH, Hartley JA, Butler J. Mechanisms of action of quinone-containing alkylating agents: DNA alkylation by aziridinylquinones. *Front Biosci*. 2000 Nov 1;5:E172-80.
- [23] Shay JW, Zou Y, Hiyama E, Wright WE. Telomerase and cancer. *Human molecular genetics*. 2001 Apr 1;10(7):677-85.
- [24] Polvani S, Calamante M, Foresta V, Ceni E, Mordini A, Quattrone A, D'Amico M, Luchinat C, Bertini I, Galli A. Acycloguanosyl 5'-thymidyltriphosphate, a thymidine analogue prodrug activated by telomerase, reduces pancreatic tumor growth in mice. *Gastroenterology*. 2011 Feb 1;140(2):709-20.
- [25] Bennewit KL, Dedhar S. Targeting hypoxic tumour cells to overcome metastasis. *BMC cancer*. 2011 Dec;11(1):1-6.
- [26] Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. *Nature Reviews Cancer*. 2011 Jun;11(6):393-410.
- [27] Page J, Berríos S, Rufas JS, Parra MT, Suja JÁ, Heyting C, Fernández-Donoso R. The pairing of X and Y chromosomes during meiotic prophase in the marsupial species *Thylamys elegans* is maintained by a dense plate developed from their axial elements. *Journal of cell science*. 2003 Feb 1;116(3):551-60.
- [28] Lindquist KE, Cran JD, Kordic K, Chua PC, Winters GC, Tan JS, Lozada J, Kyle AH, Evans JW, Minchinton AI. Selective radiosensitization of hypoxic cells using BCCA621C: a novel hypoxia activated prodrug targeting DNA-dependent protein kinase. *Tumor Microenvironment and Therapy*. 2013;1(2299-1123):46-55.
- [29] Portwood S, Lal D, Hsu YC, Vargas R, Johnson MK, Wetzler M, Hart CP, Wang ES. Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models. *Clinical Cancer Research*. 2013 Dec 1;19(23):6506-19.

- [30] Bhargava A, Vaishampayan UN. Satraplatin: leading the new generation of oral platinum agents. *Expert opinion on investigational drugs*. 2009 Nov 1;18(11):1787-97.
- [31] Mukhopadhyay S, Barnés CM, Haskel A, Short SM, Barnes KR, Lippard SJ. Conjugated platinum (IV)– peptide complexes for targeting angiogenic tumor vasculature. *Bioconjugate chemistry*. 2008 Jan 16;19(1):39-49.
- [32] Yamamoto N, Danos S, Bonnitcha PD, Failes TW, New EJ, Hambley TW. Cellular uptake and distribution of cobalt complexes of fluorescent ligands. *JBIC Journal of Biological Inorganic Chemistry*. 2008 Aug;13(6):861-71.
- [33] Erbs P, Regulier E, Kintz J, Leroy P, Poitevin Y, Exinger F, Jund R, Mehtali M. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. *Cancer Research*. 2000 Jul 15;60(14):3813-22.
- [34] Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. *Cancer research*. 1986 Oct 1;46(10):5276-81.
- [35] Parker WB, Allan PW, Shaddix SC, Rose LM, Speegle HF, Gillespie GY, Bennett Jr LL. Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. *Biochemical pharmacology*. 1998 May 15;55(10):1673-81.
- [36] Hazra S, Sabini E, Ort S, Konrad M, Lavie A. Extending thymidine kinase activity to the catalytic repertoire of human deoxycytidine kinase. *Biochemistry*. 2009 Feb 17;48(6):1256-63.
- [37] Sato T, Neschadim A, Konrad M, Fowler DH, Lavie A, Medin JA. Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. *Molecular Therapy*. 2007 May 1;15(5):962-70.
- [38] Vernejoul F, Ghénassia L, Souque A, Lulka H, Drocourt D, Cordelier P, Pradayrol L, Pyronnet S, Buscail L, Tiraby G. Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth. *Molecular therapy*. 2006 Dec 1;14(6):758-67.
- [39] Kerr DE, Senter PD, Burnett WV, Hirschberg DL, Hellström I, Hellström KE. Antibody-penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxacetamide. *Cancer Immunology, Immunotherapy*. 1990 Jul;31(4):202-6.
- [40] Yoon KJ, Qi J, Remack JS, Virga KG, Hatfield MJ, Potter PM, Lee RE, Danks MK. Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy. *Molecular cancer therapeutics*. 2006 Jun 1;5(6):1577-84.
- [41] Phelan RM, Ostermeier M, Townsend CA. Design and synthesis of a β -lactamase activated 5-fluorouracil prodrug. *Bioorganic & medicinal chemistry letters*. 2009 Feb 15;19(4):1261-3.
- [42] F Tietze L, Schmuck K. Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT. *Current pharmaceutical design*. 2011 Nov 1;17(32):3527-47.
- [43] Aboody KS, Najbauer J, Metz MZ, D'Apuzzo M, Gutova M, Annala AJ, Synold TW, Couture LA, Blanchard S, Moats RA, Garcia E. Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies. *Sci Transl Med* 5 (184): 184ra59.
- [44] Umer B, Good D, Anné J, Duan W, Wei MQ. Clostridial spores for cancer therapy: targeting solid tumour microenvironment. *Journal of toxicology*. 2012 Jan 1;2012.
- [45] Wang Y, Huang XJ. Donor Selection For Haploidentical Hematopoietic Stem Cell Transplantation: Who Is The Better– Donor-Recipient Risk Factor Analysis. *Blood*. 2013 Nov 15;122(21):705.
- [46] Fan J, Zeng F, Xu J, Wu S. Targeted anti-cancer prodrug based on carbon nanotube with photodynamic therapeutic effect and pH-triggered drug release. *Journal of nanoparticle research*. 2013 Sep;15(9):1-5.
- [47] Min Y, Li J, Liu F, Yeow EK, Xing B. Near-infrared light-mediated photoactivation of a platinum antitumor prodrug and simultaneous cellular apoptosis imaging by upconversion-luminescent nanoparticles. *Angewandte Chemie*. 2014 Jan 20;126(4):1030-4.
- [48] Ciruelos E, Jackisch C. Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer. *Expert review of anticancer therapy*. 2014 May 1;14(5):511-21.
- [49] Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumorotropic accumulation of proteins and the antitumor agent smancs. *Cancer research*. 1986 Dec 1;46(12 Part 1):6387-92.
- [50] Conner SD, Schmid SL. Regulated portals of entry into the cell. *Nature*. 2003 Mar;422(6927):37-44.
- [51] Li C, Wallace S. Polymer-drug conjugates: recent development in clinical oncology. *Advanced drug delivery reviews*. 2008 May 22;60(8):886-98.
- [52] Wong AD, DeWit MA, Gillies ER. Amplified release through the stimulus triggered degradation of self-immolative oligomers, dendrimers, and linear polymers. *Advanced drug delivery reviews*. 2012 Aug 1;64(11):1031-45.
- [53] Liu Z, Sun X, Nakayama RN, Dai H. ACS Nano 2007, 1, 50–56; b) S. Dhar, Z. Liu, J. Thomale, H. Dai, SJ Lippard. *J. Am. Chem. Soc.* 2008;130:11467-76.
- [54] Liu Z, Sun X, Nakayama-Ratchford N, Dai H. ACS Nano 2007, 1, 50–56 [ACS Full Text ACS Full Text]. Google Scholar There is no corresponding record for this reference. 2008.
- [55] Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt (IV) prodrug-PLGA–PEG nanoparticles. *Proceedings of the National Academy of Sciences*. 2008 Nov 11;105(45):17356-61.
- [56] Zhang G, Zhang M, He J, Ni P. Synthesis and characterization of a new multifunctional polymeric prodrug paclitaxel– polyphosphoester–folic acid for targeted drug delivery. *Polymer Chemistry*. 2013;4(16):4515-25.
- [57] Jung B, Jeong YC, Min JH, Kim JE, Song YJ, Park JK, Park JH, Kim JD. Tumor-binding prodrug micelles of polymer–drug conjugates for anticancer therapy in HeLa cells. *Journal of Materials Chemistry*. 2012;22(18):9385-94.
- [58] Jensen SS, Andresen TL, Davidsen J, Høyrup P, Shnyder SD, Bibby MC, Gill JH, Jørgensen K. Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids. *Molecular cancer therapeutics*. 2004 Nov 1;3(11):1451-8.
- [59] Kreitman RJ, Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. *Clinical Cancer Research*. 2011 Oct 15;17(20):6398-405.
- [60] Ogata M, Fryling CM, Pastan I, FitzGerald DJ. Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol. *Journal of Biological Chemistry*. 1992 Dec 15;267(35):25396-401.

- [61] Hervent AS, De Keulenaer GW. Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics. International journal of molecular sciences. 2012 Oct;13(10):12268-86.

